Literature DB >> 7815312

Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis.

J R Wade1, S L Beal, N C Sambol.   

Abstract

The influence of the choice of pharmacokinetic model on subsequent determination of covariate relationships in population pharmacokinetic analysis was studied using both simulated and real data sets. Simulations and data analysis were both performed with the program NONMEM. Data were simulated using a two-compartment model, but at late sample times, so that preferential selection of the two-compartment model should have been impossible. A simple categorical covariate acting on clearance was included. Initially, on the basis of a difference in the objective function values, the two-compartment model was selected over the one-compartment model. Only when the complexity of the one-compartment model was increased in terms of the covariate and statistical models was the difference in objective function values of the two structural models negligible. For two real data sets, with which the two-compartment model was not selected preferentially, more complex covariate relationships were supported with the one-compartment model than with the two-compartment model. Thus, the choice of structural model can be affected as much by the covariate model as can the choice of covariate model be affected by the structural model; the two choices are interestingly intertwined. A suggestion on how to proceed when building population pharmacokinetic models is given.

Mesh:

Substances:

Year:  1994        PMID: 7815312     DOI: 10.1007/bf02353542

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  31 in total

1.  Population pharmacokinetics of intravenous indomethacin in neonates with symptomatic patent ductus arteriosus.

Authors:  D B Wiest; J B Pinson; P S Gal; R C Brundage; S Schall; J L Ransom; R L Weaver; D Purohit; Y Brown
Journal:  Clin Pharmacol Ther       Date:  1991-05       Impact factor: 6.875

2.  Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group.

Authors:  S R Gitterman; G L Drusano; M J Egorin; H C Standiford
Journal:  Clin Pharmacol Ther       Date:  1990-08       Impact factor: 6.875

3.  Application of NONMEM to routine bioavailability data.

Authors:  D A Graves; I Chang
Journal:  J Pharmacokinet Biopharm       Date:  1990-04

4.  Population pharmacokinetics and pharmacodynamics of thiopental: the effect of age revisited.

Authors:  D R Stanski; P O Maitre
Journal:  Anesthesiology       Date:  1990-03       Impact factor: 7.892

5.  Experience with NONMEM: analysis of serum concentration data in patients treated with mexiletine and lidocaine.

Authors:  S Vozeh; M Wenk; F Follath
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

6.  Pharmacokinetics of the digoxin-quinidine interaction via mixed-effect modelling.

Authors:  P J Williams; J Lane; W Murray; M A Mergener; M Kamigaki
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

7.  Population pharmacokinetic analysis of didanosine (2',3'-dideoxyinosine) plasma concentrations obtained in phase I clinical trials in patients with AIDS or AIDS-related complex.

Authors:  S M Pai; U A Shukla; T H Grasela; C A Knupp; R Dolin; F T Valentine; C McLaren; H A Liebman; R R Martin; K A Pittman
Journal:  J Clin Pharmacol       Date:  1992-03       Impact factor: 3.126

8.  Population pharmacokinetics of lithium.

Authors:  D M Jermain; M L Crismon; E S Martin
Journal:  Clin Pharm       Date:  1991-05

9.  Netilmicin in the neonate: population pharmacokinetic analysis and dosing recommendations.

Authors:  K Fattinger; S Vozeh; A Olafsson; J Vlcek; M Wenk; F Follath
Journal:  Clin Pharmacol Ther       Date:  1991-07       Impact factor: 6.875

10.  Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates.

Authors:  L Collart; T F Blaschke; F Boucher; C G Prober
Journal:  Dev Pharmacol Ther       Date:  1992
View more
  24 in total

Review 1.  Recommended reading in population pharmacokinetic pharmacodynamics.

Authors:  Peter L Bonate
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

2.  A genetic algorithm-based, hybrid machine learning approach to model selection.

Authors:  Robert R Bies; Matthew F Muldoon; Bruce G Pollock; Steven Manuck; Gwenn Smith; Mark E Sale
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-28       Impact factor: 2.745

3.  Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model.

Authors:  P Jacqmin; E Snoeck; E A van Schaick; R Gieschke; P Pillai; J-L Steimer; P Girard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-19       Impact factor: 2.745

4.  Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide.

Authors:  Sophie Callies; Valérie André; Bharvin Patel; David Waters; Paul Francis; Michael Burgess; Michael Lahn
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

5.  Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery.

Authors:  Christine E Staatz; Colette Byrne; Alison H Thomson
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

6.  Use of prior information to stabilize a population data analysis.

Authors:  Per O Gisleskog; Mats O Karlsson; Stuart L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-12       Impact factor: 2.745

Review 7.  A genetic algorithm based global search strategy for population pharmacokinetic/pharmacodynamic model selection.

Authors:  Mark Sale; Eric A Sherer
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

8.  Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam.

Authors:  M Hossain; E Wright; R Baweja; T Ludden; R Miller
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

Review 9.  What is the best size descriptor to use for pharmacokinetic studies in the obese?

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

10.  A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979).

Authors:  Sophie Callies; Dinesh P de Alwis; Adrian Harris; Paul Vasey; Jos H Beijnen; Jan H Schellens; Michael Burgess; Leon Aarons
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.